Thank you, path Paul.
I'll continue ahead. with our WVE-XXX and detail more on
with results our trial well dosed potent preservation intrathecally of preclinical shared mutant from translation end safe to In at this and SELECT-HD Multi-dosing our generally was plus we excellent reminder, June. of tested modeling a XX% we durable huntingtin tolerated. of up and the we weeks, saw and of every huntingtin. wild-type As XX-milligram study, reductions X
reasonably before between biomarkers community potential and known key where of a of already opinion was a to the caudate correlation a significant in an clinical field, this of including reductions potent areas field rate rallying urgency XX% point and therapies giving For the HD ways caudate efficient trial predict observed symptom clinical in the Since the X% huntingtin it onset setting caudate clinical in to of behind the approval.
The there atrophy, HD outcome of of predictive recognize statistically use diagnosis, correlations notable onset clinical marked biomarker about and caudate of designs, of are many patients the in in years first and to outcomes.
It's leaders and are loss we of symptom Caudate and time atrophy, likely approval. continues more primary accelerated for the more than their the mutant that be disease X% HD brain Huntington's brain. having is begins a have one support clear is HD manifests disease-modifying lost slowing between lost the accelerated typically and a for enable volume. at first imaging loss At endpoint allele-selective to silencing. year, outcomes, be to that
pleased Dr. volume our his Just last Day. Research work on discuss to were we at Jeffrey caudate month, annual Long have
supporting conducted more designs. people It with Consortium the efficient tandem opens possibility the may delay volume clinical to C-Path and loss between enable data smaller, more also clinical During symptom living with IXICO HD-RSC atrophy, being early onset. Long's his outcomes In correlation predicting or shared of of of the CHDI, relationship for HD. Long with in would function intervention prevent Dr. delays presentation, trial efficient work caudate significant that work, enable This is slower between trials. the the Dr. rates caudate and predictive with
outcome. receptive on engagement FDA's for with this and has are a recognizes for the therapies the news advocated agency The community, successful focus caudate for is accelerated initial life-threatening on is and feedback to predict our ALS.
With Our as for to investigation from The has FDA supportive. to other with data supportive who FDA, feedback serious aspects is open the HD development the including endpoint HD our have potential initial clinical the further such progression long now IND of of to been and agency accelerated of emulating matter they approaches half and the an from second us finalization welcome potentially approval. biomarkers, to and positive engaged atrophy potential a as diseases indicated application severity key the HD study, pathway of plan evaluate on XXXX. II/III global of submission planning including of in the neurodegenerative of Phase registrational very an design for
was skipping. every September, FORWARD-XX exon of announced with in The WVE-NXXX, are investigated study DMD X Turning is from after dosing who analysis kilogram II amenable data being we In XX boys ongoing positive per an oligonucleotide which XX-milligram interim to DMD. interim XX Phase XX weeks to weeks. the skipping conducted exon of
or We adverse was There and there intensity were and mild safe pleased safety also events were oligonucleotide serious discontinuations. well were treatment-related events as study class-related that no adverse in WVE-NXXX to are events. observe no tolerated
conjugates. such, reminder, for a As hypomagnesemia. muscle not delivery not WVE-NXXX at conjugate-related And events leverage patients are such does as risk as
of mean by observed expression as measured we Additionally, Western Blot. dystrophin X% muscle content-adjusted
Becker dystrophin also consistent normal. with X% observed consistent displayed expression ambulant from patients exceeding isoforms Importantly, having with XX% boys in milder dystrophy muscular disease. The quantified was of those X highly who dystrophin levels of was expression
progenitor that to cells therapeutic muscle mean in the remarkably been skeletal muscle gram myoblasts of myogenic WVE-NXXX are We regeneration. nuclei also and to XX,XXX new and remains distribute the rise has nanograms shown to ultimately only that give aid stem DMD XX%, per cells. myogenic in myocyte concentrations myocytes WVE-NXXX for and mean new cells, exon which observed skipping stem of detected
study through the analysis Looking of from assessments we dystrophin additional treatment. well deliver of expect after final of of ahead, first the as data functional XXXX. data the year a to quarter These point will treatment weeks XX include quantification of time in as safety
to our pathway this boys, a would who are gratitude on like to FDA the staff express families study. and quarter participating of approval from accelerated deepest feedback in expect also We study the continue first XXXX.
I to the to in
the Turning patients RestorAATion-X the to who we PiZZ WVE-XXX. proof ongoing mechanism with positive Phase Ib/IIa announced of have AATD mutation. from In data October, homozygous in study
As volunteers patients. and program in our RestorAATion RestorAATion-X consists clinical you of may healthy homozygous RestorAATion-X recall, parts: ZZ X in
in mechanism of we've X, single of any top protein, AAT. total of multi-dosing results, the editing, and dose so patients RestorAATion-X than WVE-XXX. imbalances a those treatment studies.
We discontinuations. circulating at were do especially There adverse following to with that All reach were was seen Remember, XX data we've escalated confirmation reached safe the for dose disclosed seeing the patients as groups, these to line patients safety adverse of first greater of first day events moderate we no RestorAATion-X Cohort the day micromolar Cohort no we tolerable were placebo not X healthy study.
Among by X.X profile had X of protein serious any the mean well in no XX encouraged data durable events wild-type than at and rapid profile proof in RestorAATion-X planned across for make and in the Our and seen as XX, volunteers the from between of more to cohort levels X as and included meaning X observed a healthy levels and reach safety patient remarkable. representing final cohort M-AAT XX% ZZ day M-AAT
convert heterozygous goal our to is XX% from the induce the patients homozygous to at to Additionally, editing phenotype. ZZ least MZ
increased meeting for basis that approval at the the already been therapies. time XX.X So AAT AAT XX% regulatory that level to fact the level, we the at are dose very is X-week in micromolar this total point encouraging.
Mean of has augmentation first
almost AAT levels single through day early post and data in baseline dose. for These observed XX, or and X increases total dosing. from as monthly early M-AAT meaning Additionally, X day longer were as potential suggests months
data is in Kyle? multi-dose share to data Kyle The provide we restored data like on preclinical to protein that, our turn expect be RestorAATion-X more call the with our update I'd our on even with ongoing, based financials. over and study from chemistry, to and an Moran, multi-dosing. Additionally, clinical expect we XXXX.
With PN to to trial CFO, the
